Navigation Links
Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra® Treatment in Patients With Primary Immunodeficiencies
Date:3/21/2011

KING OF PRUSSIA, Pa., March 21, 2011 /PRNewswire/ -- Data presented by CSL Behring today suggest that treatment with higher dose Hizentra® (IgPro 20) correlates with reduced risk of infection and missed school or work among patients with primary immunodeficiencies (PI). These data, presented at the 2011 American Academy of Allergy, Asthma and Immunology annual meeting, derived from two recent trials of Hizentra, one performed in the United States and one in the European Union, and aimed to show the relationship between subcutaneous IgG (SCIg) dosage and clinical outcomes. Earlier studies have shown that higher immunoglobulin G (IgG) doses by intravenous (IVIg) infusion result in higher serum IgG and therefore fewer infections.(1, 2) Hizentra is indicated for the treatment of patients with PI.

The study population comprised 46 patients—19 of whom were previously on SCIg—on a dose of 120 milligrams/kilogram body-weight (mg/kg bw) (mean of medians) and 38 patients on a dose of 208.2 mg/kg bw SCIg (mean of medians). Efficacy was assessed over 28 or 54 weeks.

Although both studies demonstrated clear evidence of effectiveness with zero acute serious bacterial infections (aSBIs), patients on the higher of the two doses of SCIg experienced a lower rate of infection (2.76 vs. 5.18 infections/patient/year) and fewer days missed from school/work (2.06 vs. 8.0 days/patient/year). Importantly, the lowest blood level of IgG following a dose increased by 23.8 percent in those patients on the higher dose of SCIg, compared to 8.6 percent in those on the lower dose of SCIg.

"These data suggest that the higher dose of Hizentra provides greater protection from infection and its consequences in patients with primary immunodeficiencies," said Dr. John Hagan, Assistant Professor of Medicine in the Divisions of Allergic Diseases and Primary Immunodeficiencies of the Mayo Clinic in Rochester, MN and lead author of the stu
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. In a Phase 2 Study PF-04523655 (RTP801I-14) Showed Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema at 12 Months
2. Study of Patients on Chronic Opioid Therapy finds Likely Non-adherent Patients Have Increased Healthcare Costs, More Hospital Days
3. iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
4. Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study
5. Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint
6. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
7. Six-Month Prospective Multi-Center Study Reports Efficacy Rates for AMS Elevate Anterior and Apical Prolapse Repair System
8. BioTox Sciences (BTS) Deploys eStudy™ Hosted Solution for Management of GLP & Non-GLP Preclinical Studies
9. Positive Findings From Excellagen Matrix Clinical Study Published in Peer-Reviewed Journal Wound Repair and Regeneration
10. DATATRAK Awarded First Study With Kreara Solutions
11. Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... and PARIS , July 28, 2015 ... Sanofi have entered into a new global collaboration to ... the emerging field of immuno-oncology. As part of the ... cell death protein 1 (PD-1) inhibitor currently in Phase ... 2016 with new therapeutic candidates based on ongoing, innovative ...
(Date:7/27/2015)... United Kingdom , July 27, 2015 /PRNewswire/ ... a leading specialty biopharmaceutical company, announced today that ... which it will sell its global contrast media ... NYSE Euronext) in a transaction valued at approximately ... divest its CMDS business is consistent with the ...
(Date:7/27/2015)... and PITTSBURGH , July 27, ... that it will hold its extraordinary general meeting of shareholders ... (NYSE: PRGO ; TASE) at the Okura Hotel Amsterdam ... Time (CET). Among other agenda items at ... on the approval, under article 2:107a of the Dutch Civil ...
Breaking Medicine Technology:Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 3Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 4Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 5Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 6Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 7Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 8Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 2Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 3Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 4Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 5Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 6Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 7Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 2Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 3Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 4Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 5Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 6Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 7Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 8Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 9Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders 10
... 2011 Double Eagle Holdings, Ltd. (OTCQB: ... www.fusescience.com ), announced today that it has entered into ... Inc. (PDT Inc.), a California-based pharmaceutical consulting firm. Double ... Inc., the developer of new, patent-pending technologies poised to ...
... the worldwide leader in 3D Molecular Breast Imaging (MBI), ... the Naviscan Board of Directors. Dr. Cheng ... in the medical device industry.  He served as the ... Inc.  After acquisition by Ethicon, Inc., a Johnson & ...
Cached Medicine Technology:Double Eagle Holdings Enters Into Supply Agreement with Platform Delivery Technologies Inc. 2Double Eagle Holdings Enters Into Supply Agreement with Platform Delivery Technologies Inc. 3Naviscan Further Strengthens its Board of Directors With the Addition of Dr. Andre Cheng 2
(Date:7/28/2015)... ... 2015 , ... North American Seminars will present seventeen ... . These seventeen courses are pre-approved for CME credit for Physical therapists, ... the Older Adult , August 22, 2015 - August 23, 2015 presented ...
(Date:7/28/2015)... Orange, NJ (PRWEB) , ... July 28, 2015 , ... ... on the sidelines – or in your easy chair? Luckily, there are plenty of ... Kadimcherla, MD , an orthopedic spine surgeon at Atlantic Spine Center . ...
(Date:7/28/2015)... ... ... President of the Veterans Fund of the United States, managing the United Veteran Beacon House ... a campaign to help homeless Veterans by giving them “A hand up – not a ... the UVBH assists and supports Vets through the Veterans Fund of the United States ...
(Date:7/27/2015)... ... ... Dr. Robert G. Schwartz , principal of Greenville, SC-based Piedmont Physical Medicine ... in order to offer his patients a new system of care utilizing laser therapy ... Peripheral neuropathy is a disease caused by damage to the peripheral nerves, and typically ...
(Date:7/27/2015)... ... July 28, 2015 , ... Combination Product GMP Compliance:, Understanding FDA’s ... EDT, http:// http://www.fdanews.com/comboproductgmpcompliance , Manufacturing a drug or device is ... things can get messy in a hurry. In a 46-page draft guidance released in ...
Breaking Medicine News(10 mins):Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 2Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 3Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 4Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 5Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 6Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 7Health News:North American Seminars receives California PT Board approval for Seventeen Continuing Education Courses presented in the Fall of 2015. 8Health News:Safe Cardio for Back Pain Sufferers 2Health News:Safe Cardio for Back Pain Sufferers 3Health News:Veterans Fund of the United States Launches “Adopt A Homeless Veteran” Campaign 2Health News:Veterans Fund of the United States Launches “Adopt A Homeless Veteran” Campaign 3Health News:Piedmont Physical Medicine & Rehabilitation, P.A. Partners with Realief® Neuropathy Centers to Offer Peripheral Neuropathy Laser Treatment 2Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 2Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 3Health News:FDAnews Announces — Combination Product GMP Compliance: Understanding FDA’s New Streamline Approach Webinar, Aug. 19, 2015 4
... progression, mouse study suggests , , MONDAY, April 14 (HealthDay ... cholesterol and one is an anti-inflammatory -- may be ... presented at the American Association for Cancer Research annual ... and the statin Lipitor, when used together or alone, ...
... Kimmel Cancer Center at Thomas Jefferson University in ... blood pressure medications might help prevent the spread ... laboratory that one type of pressure-lowering drug called ... growth and causes cell death. , In earlier ...
... Real-Time In Vivo Data via Quantitative ... ... Inc., a leader,in fluorescence in vivo imaging, today announced the commercial ... is based on VisEn,s,proprietary Fluorescence Molecular Tomography (FMT(TM)) technology,platform, and combined ...
... 14 HealthFusion, a,national clearinghouse for ... center operation customer satisfaction excellence under ... Center Program(SM). This distinction,acknowledges a strong ... to provide "An Outstanding Customer Service ...
... As the first of the,nation,s 78 million baby boomers ... health care work force that is too small and ... new report from the Institute of,Medicine. The report calls ... providers -- not just specialists -- in the basics ...
... Denise Kehoe has joined,medication therapy management (MTM) company ... new role, she will manage and oversee the,expansion ... the country., Kehoe brings more than 15 ... PharmMD. She recently served as national strategic,executive of ...
Cached Medicine News:Health News:Celebrex Plus Lipitor Could Fight Prostate Cancer 2Health News:Celebrex Plus Lipitor Could Fight Prostate Cancer 3Health News:Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find 2Health News:VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System 2Health News:J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience 2Health News:J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience 3Health News:Health Care Work Force Too Small, Unprepared for Aging Baby Boomers; Higher Pay, More Training, and Changes in Care Delivery Needed to Avert Crisis 2Health News:PharmMD Announces Denise Kehoe as Vice President of Business Development 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: